Neuroimaging biomarkers for neurologic infections are significant devices, both for understanding pathology related with mental and clinical side effects and for differential diagnosis. This section investigates neuroimaging measures, including underlying and practical measures from magnetic resonance imaging (MRI) and subatomic measures principally from positron emission tomography (PET), in sound maturing grown-ups and in various neurologic illnesses. The range covers neuroimaging measures from typical maturing to different dementias: late-beginning Alzheimer’s disease [AD; mild cognitive impairment (MCI)], familial and non-familial beginning stage Promotion, abnormal Advertisement conditions, posterior cortical atrophy (PCA), Parkinson’s sickness (PD) with and without dementia, and multiple systems atrophy (MSA). We likewise incorporate a conversation of the appropriate use criteria (AUC) for amyloid imaging and finish up with a conversation of differential finding of neurologic dementia issues with regards to neuroimaging.